Chemomab Therapeutics - CMMB Profit before deduction of interest, taxes, depreciation and amortization
Chemomab Therapeutics (CMMB) is implementing ESG principles by reducing chemical waste during the development of fibrosis treatments. This EBITDA trend on the current GURU.Markets chart shows that 0.00 is the current metric value. However, financial stability is limited by the risk of failed trials, and a high dependence on a single drug in the portfolio creates a serious vulnerability in the business model.
Summary analytical data breakdowns for Chemomab Therapeutics Ltd. (CMMB)
- stock value and consensus price forecast:
- issuer market value details:
- book capitalization indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Chemomab Therapeutics|CMMB - Long-Term Debt to Equity|Current Liabilities to Equity Chemomab Therapeutics Ltd|CMMB - Company Aggregate Debts|Debt to Net Assets Ratio Chemomab Therapeutics|CMMB - Company Long-Term Debts|Company Short-Term Debts Chemomab Therapeutics|Intermediate Coverage Ratio chemomab.com
- earnings and market multiples details:
CMMB - Company Net Income|Future Profit Chemomab Therapeutics|CMMB - P/E Multiple|Forward P/E Multiple Chemomab Therapeutics Ltd|CMMB - PEG Multiple|Enterprise Value to EBITDA Ratio Chemomab Therapeutics|CMMB - Operating profit EBITDA|Earnings per share for the trailing year Chemomab Therapeutics|CMMB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months chemomab.com|CMMB - Earnings per share growth in current year|Expected earnings per share growth for next year Chemomab Therapeutics
Summary company analytics:Chemomab Therapeutics
An investment audit of Chemomab Therapeutics (CMMB) requires an analysis of actual commercial cash flows to assess business viability. This metric captures daily operating income adjusted for non-cash charges, which, in a biotech environment with a minimal ecological footprint and costs limited to waste disposal, allows the EBITDA trend to differentiate seasonal fluctuations from a systemic crisis.
Who Chemomab Therapeutics competes with
Operating income before deduction of amortization Vertex Corp (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BioMarin Pharmaceutical Inc. (BMRN)|BBIO (BridgeBio Pharma Inc) - Operating profit EBITDA|Operating profit before amortization BGM (BGM Group Corp)|Operating profit before deduction of amortization COGT (Cogent Biosciences)|XERS (xerispharma.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Keros Therapeutics, Inc. KROS|ARCT (Arcturus Therapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Eton Pharma - Operating profit EBITDA|Income before deduction of interest, taxes and amortization KMDA (Kamada Pharma)|FULC: Operating profit EBITDA|Abeona Therapeutics Inc. (ABEO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Mereo BioPharma Group|PLX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pliant Therapeutics (PLRX)|Operating profit before deduction of amortization appliedtherapeutics.com APLT|Operating profit EBITDA RNTX (Rein Therapeutics Inc)|Operating profit EBITDA Gelteq Ltd GELS|Aytu Therapeutics - Operating profit EBITDA|SRx Health Solutions Inc. (SRXH) - Operating profit before deduction of amortization|PLRZ: Operating profit EBITDA|Aeterna Zentaris Inc. - Income before deduction of interest, taxes and amortization|CYTH (Cyclo Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Inozyme INZY|Profit before payment of interest, taxes and amortization Reneo Pharmaceuticals, Inc. (RPHM)|Operating profit before deduction of amortization COSCIENS Biopharma Inc CSCI
